| A reference map of the human binary protein interactome K Luck, DK Kim, L Lambourne, K Spirohn, BE Begg, W Bian, R Brignall, ... Nature 580 (7803), 402-408, 2020 | 953 | 2020 |
| Widespread expansion of protein interaction capabilities by alternative splicing X Yang, J Coulombe-Huntington, S Kang, GM Sheynkman, T Hao, ... Cell 164 (4), 805-817, 2016 | 555 | 2016 |
| Systems analysis of intracellular pH vulnerabilities for cancer therapy E Persi, M Duran-Frigola, M Damaghi, WR Roush, P Aloy, JL Cleveland, ... Nature communications 9 (1), 2997, 2018 | 349 | 2018 |
| Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker M Duran-Frigola, E Pauls, O Guitart-Pla, M Bertoni, V Alcalde, D Amat, ... Nature Biotechnology 38 (9), 1087-1096, 2020 | 117* | 2020 |
| Isolation of human colon stem cells using surface expression of PTK7 P Jung, C Sommer, FM Barriga, SJ Buczacki, X Hernando-Momblona, ... Stem Cell Reports 5 (6), 979-987, 2015 | 68 | 2015 |
| Analysis of chemical and biological features yields mechanistic insights into drug side effects M Duran-Frigola, P Aloy Chemistry & biology 20 (4), 594-603, 2013 | 58 | 2013 |
| Residues coevolution guides the systematic identification of alternative functional conformations in proteins P Sfriso, M Duran-Frigola, R Mosca, A Emperador, P Aloy, M Orozco Structure 24 (1), 116-126, 2016 | 54 | 2016 |
| Recycling side-effects into clinical markers for drug repositioning M Duran-Frigola, P Aloy Genome Medicine 4 (1), 1-4, 2012 | 54 | 2012 |
| Bioactivity descriptors for uncharacterized chemical compounds M Bertoni, M Duran-Frigola, P Badia-i-Mompel, E Pauls, M Orozco-Ruiz, ... Nature Communications 12 (1), 3932, 2021 | 51 | 2021 |
| Drug sensitivity in cancer cell lines is not tissue-specific S Jaeger, M Duran-Frigola, P Aloy Molecular cancer 14, 1-4, 2015 | 51 | 2015 |
| Structural systems pharmacology: the role of 3D structures in next-generation drug development M Duran-Frigola, R Mosca, P Aloy Chemistry & biology 20 (5), 674-684, 2013 | 51 | 2013 |
| A community challenge for a pancancer drug mechanism of action inference from perturbational profile data EF Douglass, RJ Allaway, B Szalai, W Wang, T Tian, A Fernández-Torras, ... Cell Reports Medicine 3 (1), 2022 | 43 | 2022 |
| Detecting similar binding pockets to enable systems polypharmacology M Duran-Frigola, L Siragusa, E Ruppin, X Barril, G Cruciani, P Aloy PLOS Computational Biology 13 (6), e1005522, 2017 | 40 | 2017 |
| Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization G Moncunill, A Scholzen, M Mpina, A Nhabomba, AB Hounkpatin, ... Science translational medicine 12 (543), eaay8924, 2020 | 37 | 2020 |
| Connecting chemistry and biology through molecular descriptors A Fernández-Torras, A Comajuncosa-Creus, M Duran-Frigola, P Aloy Current Opinion in Chemical Biology 66, 102090, 2022 | 36 | 2022 |
| Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque A Fernández-Torras, M Duran-Frigola, M Bertoni, M Locatelli, P Aloy Nature communications 13 (1), 5304, 2022 | 34 | 2022 |
| Systems-Wide Prediction of Enzyme Promiscuity Reveals a New Underground Alternative Route for Pyridoxal 5’-Phosphate Production in E. coli MA Oberhardt, R Zarecki, L Reshef, F Xia, M Duran-Frigola, R Schreiber, ... PLoS computational biology 12 (1), e1004705, 2016 | 32 | 2016 |
| A chemo-centric view of human health and disease M Duran-Frigola, D Rossell, P Aloy Nature communications 5 (1), 5676, 2014 | 32 | 2014 |
| IntSide: a web server for the chemical and biological examination of drug side effects T Juan-Blanco, M Duran-Frigola, P Aloy Bioinformatics 31 (4), 612-613, 2014 | 31 | 2014 |
| Dual fluorescence in 9-amino-2, 7, 12, 17-tetraphenylporphycene M Duran-Frigola, R Tejedor-Estrada, D Sánchez-García, S Nonell Physical Chemistry Chemical Physics 13 (21), 10326-10332, 2011 | 29 | 2011 |
Patrick AloyICREA Research Professor at the Institute for Research in Biomedicine在 irbbarcelona.org 的电子邮件经过验证
